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A B S T R A C T
Purpose: Hypertrophic cardiomyopathy (HCM) is characterized by a heterogeneous morphology and variable
prognosis. A mismatch between left ventricular mass (LVM) and microvascular circulation with corresponding
relative ischemia has been implicated to cause myocardial replacement ﬁbrosis that deteriorates prognosis.
Besides parametric T1 mapping, Cardiovascular Magnetic Resonance (CMR) T2* mapping is able to identify
ischemia as well as ﬁbrosis in cardiac and extracardiac diseases. Therefore, we aimed to investigate the value of
T2* mapping to characterize structural alterations in patients with HCM.
Methods: CMR was performed on a 1.5 T MR imaging system (Achieva, Philips, Best, Netherlands) using a 5-
channel coil in patients with HCM (n=103, 50.6 ± 16.4 years) and in age- and gender-matched controls
(n=20, 44.8 ± 16.9 years). T2* mapping (1 midventricular short axis slice) was acquired in addition to late
gadolinium enhancement (LGE). T2* values were compared between patients with HCM and controls as well as
between HCM patients with- and without ﬁbrosis.
Results: HCM patients showed signiﬁcantly decreased T2* values compared to controls (26.2 ± 4.6 vs.
31.3 ± 4.3ms, p < 0.001). Especially patients with myocardial ﬁbrosis presented with decreased T2* values in
comparison to those without ﬁbrosis (25.2 ± 4.0 vs. 28.7 ± 5.3ms, p=0.003). A regression model including
maximum wall thickness, LVM and T2* values provided good overall diagnostic accuracy of 80% to diagnose
HCM with and without ﬁbrosis.
Conclusion: In this study, parametric mapping identiﬁed lower T2* values in HCM patients compared to controls,
especially in a sub-group of patients with myocardial ﬁbrosis. As myocardial ﬁbrosis has been suggested to
inﬂuence prognosis of patients with HCM, T2* mapping may add information for identifying a higher risk sub-
group of HCM patients.
1. Introduction
Hypertrophic cardiomyopathy (HCM) is characterized by a hetero-
geneity in myocardial structure and function, clinical presentation as
well as prognosis. Increasing left ventricular mass (LVM) and wall
thickness are common endpoints to diﬀerent genetic and adaptive in-
ﬂuences and cannot solely be explained by abnormal loading conditions
of the heart [1]. On a structural level, HCM can be characterized by a
small vessel disease that may aggravate a mismatch between myo-
cardial mass and coronary blood circulation leading to myocardial is-
chemic reactions including myocyte degeneration [2–5]. Over time,
myocardial ischemia is thought to trigger myocardial replacement ﬁ-
brosis that can be seen in up to 65% of all HCM patients [1,6,7].
While HCM may exhibit a benign course, structural changes may
deteriorate prognosis and outcome. In particular, the cascade of myo-
cardial ischemia causing myocardial replacement ﬁbrosis may be
https://doi.org/10.1016/j.ejro.2019.01.007
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responsible for symptoms and an inﬂuence on mortality, heart failure
and future cardiac events [5,8–11]. This makes ﬁbrosis assessment in
HCM of additional value for the clariﬁcation of symptoms, risk strati-
ﬁcation and prognosis [3].
In addition to echocardiography, Cardiovascular Magnetic
Resonance (CMR) is proposed a class IB recommendation for the di-
agnosis of HCM [1]. Besides morphology, CMR is able to provide in-
sights into structural alterations by characterizing areas of ﬁbrosis and
scarring using late gadolinium enhancement (LGE) or post-contrast
quantitative T1-mapping. For HCM, CMR perfusion studies with con-
trast agents have already detected a group of patients with localized
microvascular dysfunction that is associated with myocardial ischemia
and ﬁbrosis [8,12]. However, in terms of further structural character-
ization and because not all HCM patients are able to receive contrast
agents due to contraindications such as renal failure, T2* magnetic
relaxation parameters (parametric mapping) have been exploited to
visualize mesoscopic (structure of the tissue) magnetic ﬁeld in-
homogeneities [13–15]. For instance, T2* was demonstrated to char-
acterize ﬁbrosis in extracardiac tissues such as the intestinal tract, but
also in ischemic and ﬁbrotic segments after myocardial infarction
[15–18]. In addition, histopathologic substrates of T2* and a correla-
tion of T2* to ﬂow analyses have already been studied in aﬀected tis-
sues [16,17,19,20]. The diagnostic value of T2* mapping during the
course of HCM has not been investigated yet, but according to recent
literature and structural alterations including relative ischemia and ﬁ-
brosis, decreased T2* vales can be suggested [8,12].
Therefore, we aimed to investigate the value of parametric T2*
mapping to describe structural alterations, especially ﬁbrosis, in a
group of patients displaying HCM.
2. Materials and methods
The study was conducted in accordance to the Declaration of
Helsinki and its later amendments. All data used for this study were
acquired for clinical purposes and handled anonymously. This retro-
spective study had ethics committee approval. Written informed con-
sent requirement was waived.
2.1. Study population
In total, 103 patients with HCM were retrospectively analyzed with
a CMR performed between June 2012 and May 2018. The patients were
referred for clinical evaluation in our HCM outpatient clinic, in which
patients are followed according to a speciﬁed care track with CMR
every 3–5 years. Diagnosis with disease was made according to the
2014 ESC Guidelines with otherwise unexplained LVH and a maximal
wall thickness ≥ 15mm [1]. Most of the patients with implantable
cardioverter deﬁbrillators had to be excluded from the study due to
safety guidelines. Patients with CAD using prior cardiac catheterization
or non-invasive imaging were excluded due to a reduction of T2* values
in ischemic segments [15,20]. Assuming decreased T2* values in the
group of HCM, we sought to identify an eﬀect in comparison to normal
controls with a statistical power of 90% and type I error of less than
2.5%, resulting in an estimated sample size of 19 for the control group.
Therefore, 20 age- and gender matched controls without myocardial
hypertrophy of any cause or familiar predisposition of HCM were ad-
ditionally evaluated through our outpatient clinic. To account for an
inﬂuence of comorbidities, those parameters were matched as well.
2.2. Cardiovascular magnetic resonance
CMR was performed on a 1.5 T MRI System (Achieva, Philips, Best
Netherlands) using a 5-channel phased array coil. After scout and re-
ference scans, functional and geometric assessment was performed
using cine steady state free precession (SSFP) images in standard long
axis geometries (two-, three- and four-chamber view) as well as in short
axis orientation with full ventricular coverage from base to apex
(Repetition time (TR)/echo time (TE)= 3.3/1.6 ms, ﬂip angle
(FA)= 60°, spatial resolution=1.5× 1.5× 8 mm3, 50 phases, 2 slices
per breath-hold) [15].
T2*-mapping was performed using a single-breath-hold multi-echo
fast ﬁeld-echo sequence in one short axis midventricular slice at end-
diastole (6 echoes with shortest interecho spacing of 1.7 ms, TE: 3ms,
TR: 13ms, ﬂip angle 35°, acquired spatial resolution 1.6×2.8×8
mm3, reconstructed spatial resolution: 1.2× 1.2×8 mm3, bandwidth
781 Hz/pixel) [15]. All HCM patients were eligible (glomerular ﬁltra-
tion rate (GFR)>35ml/min) to receive gadolinium-based contrast
agent (Gadovist, Bayer Healthcare, Berlin, Germany 0.2 mmol/kg) for
late gadolinium enhanced imaging (LGE) in order to detect myocardial
scarring or ﬁbrosis. After 15min, a 3-dimensional gradient spoiled
turbo fast-ﬁeld-echo sequence with a non-selective 180° inversion pre-
pulse was acquired at end-diastole with anatomical reference taken
from SSFP images [21].
2.3. Post processing
Post-processing was performed using commercial software (Cardiac
MR Viewer, IntelliSpace Portal Version 8.0, Philips, Best, The
Netherlands). Short and long axis slices were analyzed covering max-
imum end-diastolic interventricular septum thickness (IVS) at max-
imum extension, left and right ventricular end-diastolic volume indexed
to body surface area (LVEDVi/RVEDVi), left and right ventricular
ejection fraction (LVEF/RVEF), and LVM indexed to body surface area
(LVMi).
T2* sequences were post-processed by one experienced observer
(> 3 years in cardiac imaging) and according to recent guidelines: a
region of interest (ROI) was manually drawn within the IVS of the
midventricular slice using a standardized ROI size (≈50mm2) and
avoiding partial volume eﬀects at epicardial boarders (Fig. 1) [22]. This
has been shown feasible in previous studies in addition to avoid sus-
ceptibility artifacts [23,19]. For every ROI, the time constant of the
signal intensity decay over all echoes was derived by ﬁtting a mono-
exponential decay curve. Afterwards, average T2* values and standard
deviations (SD) for the ROI were calculated and color-coded using a
spectral look-up table. T2* measurements were repeated in 20 subjects
by a second experienced observer (> 3 years in cardiac imaging) to test
interobserver agreement.
For LGE imaging, the amount of ﬁbrosis was calculated semi-auto-
matically by manually applying epi- and endocardial contours to the
short axis LGE images in every slice. Additional ROIs were placed
within the hyperenhanced and normal appearing myocardium using the
software and reviewed by the reader. Afterwards, the amount of ﬁbrosis
was calculated by using a full-width at half-maximum (FWHM)
Fig. 1. T2* measurement within the IVS of a midventricular slice of a patient
with HCM by placing a standardized ROI.
HCM, hypertrophic cardiomyopathy; IVS, interventricular septum; ROI, region
of interest.
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algorithm in which a multi-pass region-growing algorithm enabled to
identify the boundaries of the ﬁbrotic segments [24,25]. The percen-
tage of ﬁbrotic tissue as % to total LVM was calculated.
2.4. Statistical analysis
Statistical analysis was performed using SPSS (version 24.0, IBM,
Armonk, NY, US). Unless otherwise stated, continuous variables are
presented as mean ± SD. Normal distribution was tested using the
Kolmogorov-Smirnov test. Categorical variables are reported as per-
centages. Data between two diﬀerent groups were analyzed by 2-sided
unpaired Student’s t-tests for normally distributed data and Mann-
Whitney U-tests for not normally distributed data. Fisher’s exact t-test
was used to examine signiﬁcant diﬀerences between nominal classiﬁ-
cations. Coeﬃcient of variance (CoV) for interobserver agreement was
calculated by taking the SD of the diﬀerences divided by the mean
values.
Pearsons correlation was performed to analyze correlations between
diﬀerent CMR parameters including T2* values. Variables with a uni-
variate statistical signiﬁcance were entered into a stepwise binomial
logistic regression model to diﬀerentiate HCM with and without ﬁbrosis
(+/- LGE). In the end, receiver operating characteristics (ROC) were
used to generate cut-oﬀ values to optimize sensitivity and speciﬁcity for
the diﬀerentiation between the diﬀerent groups (HCM and controls as
well as HCM+versus – LGE). P-values below 0.05 were considered as
statistically signiﬁcant.
3. Results
3.1. Patient population
The enrolled 103 HCM patients (mean age 50.6 ± 16.4 years) were
age- and sex-matched with the 20 control subjects (CMR between
August 2017 and January 2019). According to the ESC Guidelines on
HCM, 49 out of the 103 patients had a diagnosis of HOCM as deﬁned by
an instantaneous Doppler LV outﬂow tract gradient> 30mmHg at rest
and/or during provocation [1]. Clinical baseline characteristics are
summarized in Table 1.
3.2. CMR parameters in HCM compared to controls
Baseline CMR characteristics of all patients compared to controls are
displayed in Table 2. HCM patients showed signiﬁcantly elevated IVS
and LVMi. Although being diﬀerent, LVEF was preserved in both groups
according to recent heart failure guidelines [26]. T2* values were sig-
niﬁcantly decreased for patients with HCM in comparison to the control
group (26.2 ± 4.6 vs. 31.3 ± 4.3ms, p < 0.001) (Figs. 2 and 3). A
further division of HCM patients in HOCM and HNCM is displayed in
Table 2. Despite exhibiting a signiﬁcant diﬀerence in IVS and LVMi (all
increased in HOCM), there was no signiﬁcant diﬀerence in T2* values
between HOCM and HNCM. T2* measurement showed a good inter-
observer variability with a CoV of 6.0%.
There was no signiﬁcant correlation between T2* values and body
surface area. Although being signiﬁcant, the correlations between T2*
values and age (R = -0.22, p=0.016), IVS (R=-0.36, p < 0.001) and
LVMi (R=-0.24, p=0.008) were weak. Men and women exhibited no
signiﬁcant diﬀerence in T2* values (27.1 ± 4.8ms for men and
26.8 ± 5.4ms for women).
The signiﬁcant CMR parameters between HCM and controls were
further entered into receiver operating characteristics. ROC analysis
identiﬁed IVS (are under the curve (AUC): 1.0) and LVMI (AUC: 0.93)
as the best parameters to diﬀerentiate between those groups. T2* values
showed a slightly higher area under the curve (AUC: 0.80) in com-
parison to LVEF (AUC: 0.74), but not to RVEDVi (AUC: 0.84) and RVEF
(AUC: 0.87). A cut-oﬀ below 27.8ms discriminated between HCM and
controls with a sensitivity of 80% and a speciﬁcity of 62%.
3.3. CMR parameters in HCM with and without ﬁbrosis
Overall, 75 out of 103 HCM patients (73%) displayed left ven-
tricular ﬁbrosis in LGE imaging. Within the HNCM group, 39 out of 54
(72%) patients exhibited ﬁbrosis with a range of 1–38% of the LVMi.
Within the HOCM group, 35 out of 49 patients (71%) displayed LGE
with a range of 1–28%.
Separately comparing the groups of HCM patients with and without
ﬁbrosis, there was a diﬀerence in left-ventricular mass with an elevated
LVMi and a signiﬁcantly thickened IVS (Table 3) for the ﬁbrosis-group.
In addition, the ﬁbrosis-group displayed signiﬁcantly decreased T2*
values (25.2 ± 4.0 vs. 28.7 ± 5.3ms, p=0.003) (Figs. 3 and 4). Se-
parately comparing patients without ﬁbrosis to controls, the statistical
signiﬁcance for the group of HCM showed a tendency (p= 0.074). No
correlation between T2* values and the amount of ﬁbrosis, IVS and
LVMi could be detected. Vice versa, patients with T2* values below the
ﬁrst quartile did not show signiﬁcant diﬀerences in the amount of ﬁ-
brosis, IVS or LVMi.
T2* values (p=0.002), IVS (p=0.010) and LVMi (p= 0.040)
showed a signiﬁcant association to ﬁbrosis in univariate regression
model. Including those parameters into the multivariate regression
model, the model was statistically signiﬁcant, χ2(3)= 19.2,
p < 0.001, for the likelihood of having a HCM with ﬁbrosis.
Decreasing T2* values (p=0.006) and increasing IVS (p=0.070) were
associated with an increased likelihood of having a HCM with ﬁbrosis.
The model classiﬁed 80% of cases correctly with a sensitivity for ﬁ-
brosis of 96% and a speciﬁcity of 36%. Accounting for age as another
covariate, the association between ﬁbrosis and T2* (p=0.006) and IVS
(p= 0.072) remained.
Comparing the ﬁbrosis and non-ﬁbrosis group in the diﬀerent, sig-
niﬁcant CMR parameters, ROC analysis exhibited good results for T2*
values (AUC: 0.68) compared to IVS and LVMi (IVS-AUC: 0.67, LVMi-
AUC: 0.62) (Fig. 5). Choosing a cut-oﬀ below 25.3 ms, a sensitivity of
71% and speciﬁcity of 44% was calculated to diﬀerentiate between ﬁ-
brosis and non-ﬁbrosis.
4. Discussion
In the present study, T2* mapping identiﬁed reduced T2* values in
patients with HCM in comparison to a healthy control group. Within the
HCM cohort, a sub-group of patients with left-ventricular ﬁbrosis ex-
hibited most pronounced T2* value reduction. We identiﬁed optimal
cut-oﬀ values for additional diagnostic accuracy to diﬀerentiate those
Table 1
Demographic and clinical baseline characteristics.
All patients
(n=103)
Controls
(n=20)
P-value
Demographics
Age (years) 50.6 ± 16.4 44.8 ± 16.9 0.155
Male (%) 79 (77) 13 (65) 0.270
BSA (m2) 1.9 ± 0.2 2.0 ± 0.2 0.596
HOCM (%) 49 (48) – –
Family history HCM n(%) 33 (32) – –
Positive biopsy n(%) 12 (12) – –
Comorbidities
Diabetes, n(%) 6 (6) 2 (7) 0.865
Hypertension, n(%) 32 (31) 1 (5) 0.016
Hypercholesterolemia, n(%) 23 (22) 3 (15) 0.170
Renal failure (GFR < 60ml/min), n(%) 9 (9) 0 (0) 0.576
CAD, n(%) 0 (0) 0 (0) 1.00
Previous Stroke, n(%) 10 (10) 1 (5) 0.499
Class NYHA III-IV n(%) 10 (10) 0 (0) 0.146
BSA, body surface area; CAD, coronary artery diseases; GFR, glomerular ﬁl-
tration rate; HCM, hypertrophic cardiomyopathy; HOCM, hypertrophic ob-
structive cardiomyopathy; NYHA, New York Heart Association.
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groups.
An increase in LVMi and IVS are commonly used for the diagnosis of
HCM in current guidelines [1]. Results of the current IVS and LVMi
analyses are in line with those guidelines, showing good diagnostic
accuracy for the diﬀerentiation of HCM and healthy controls. However,
HCM can be characterized by additional structural and functional
changes during the course of the disease that can inﬂuence the prog-
nosis of the disease [1,8,9]. One of those alterations is microvascular
dysfunction with its pathophysiologic cascade resulting in myocardial
ﬁbrosis and scarring [8]. These structural alterations can commonly be
seen in HCM patients. Imaging modalities, such as CMR, have already
been able to correlate reduced myocardial blood ﬂow to areas of LGE in
HCM [8,27]. As the presence of ﬁbrosis in HCM patients has shown an
inﬂuence on symptoms, prognosis or cardiovascular events, there has
been a fundamental interest to identify this sub-group of patients. This
can help to eventually adapt clinical assessment strategies for a wider
range of patients that cannot be classiﬁed with common risk
Table 2
Baseline CMR characteristics in all patients compared to controls and divided into HOCM and HNCM.
All patients Controls P-value HNCM
(n=54)
HOCM
(n=49)
P-value
LVEF (%) 64.8 ± 8.4 60.1 ± 4.4 < 0.001 63.4 ± 9.5 66.4 ± 6.6 0.152
IVS (mm) 19.7 ± 4.4 8.5 ± 1.5 < 0.001 18.6 ± 4.2 20.9 ± 4.2 < 0.01
LVMi(g/m2) 85.6 ± 28.8 47.6 ± 10.7 < 0.001 81.2 ± 28.3 90.4 ± 28.9 0.065
LVEDVi (ml) 74.6 ± 16.3 78.0 ± 13.6 0.380 74.4 ± 18.1 74.7 ± 14.3 0.925
RV-EF (%) 70.0 ± 8.3 58.4 ± 7.0 < 0.001 69.4 ± 8.1 70.7 ± 8.4 0.436
RVEDVi (ml) 59.3 ± 14.6 78.5 ± 16.9 < 0.001 58.6 ± 15.6 60.0 ± 14.6 0.592
T2* (ms) 26.2 ± 4.6 31.3 ± 4.3 < 0.001 26.9 ± 5.1 25.4 ± 4.0 0.095
HNCM, hypertrophic non-obstructive cardiomyopathy; HOCM, hypertrophic obstructive cardiomyopathy; IVS, interventricular septum; LVEDVi/RVEDVi, left/right
ventricular end-diastolic volume indexed by body surface area; LVEF/RVEF, left/right ventricular ejection fraction; LVMi, left ventricular mass indexed by body
surface area.
Fig. 2. Comparison of T2* values between patients with HCM and a healthy
control group.
HCM, hypertrophic cardiomyopathy.
Fig. 3. (A) T2* map of a normal control (upper panel) compared to a patient
with HCM (lower panel) and (B) LGE image (upper panel) and corresponding
T2* map (lower panel) to visualize the reduction of T2* values in the areas of
myocardial ﬁbrosis.
HCM, hypertrophic cardiomyopathy; LGE, late gadolinium enhancement.
Table 3
Baseline CMR characteristics in patients with HCM plus ﬁbrosis (+LGE) and
without ﬁbrosis (-LGE).
+ LGE
(n=75)
- LGE
(n= 28)
P-value
LVEF (%) 64.8 ± 9.2 65.0 ± 5.6 0.870
IVS (mm) 20.4 ± 4.7 17.8 ± 2.7 0.010
LVMi(g/m2) 89.2 ± 30.7 75.8 ± 20.4 0.055
LVEDVi (ml) 74.7 ± 17.1 74.3 ± 14.4 0.922
RV-EF (%) 70.6 ± 8.8 68.6 ± 6.5 0.287
RVEDVi (ml) 58.4 ± 13.5 61.5 ± 17.2 0.544
T2* (ms) 25.2 ± 4.0 28.7 ± 5.3 0.003
HCM, hypertrophic cardiomyopathy; IVS, interventricular septum; LGE, late
gadolinium enhancement; LVEDV/RVEDV, left/right ventricular end-diastolic
volume; LVEF/RVEF, left/right ventricular ejection fraction; LVMi, left ven-
tricular mass indexed by body surface area; SV, stroke volume.
Fig. 4. Comparison of T2* values between patients with (+) and without (-)
LGE.
LGE, late gadolinium enhancement
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stratiﬁcation models [28].
The non-invasive imaging of myocardial structural alterations is one
of the core strengths of CMR, e.g. using LGE or ECV to detect ﬁbrosis
with contrast agents [29]. In fact, LGE has been described in up to 65%
of all HCM patients [7,22,30]. In the presence of contraindications to
gadolinium chelates or for further validation of structural alterations,
parametric mapping techniques without the use of contrast agents have
gained additional value to describe structural alterations in various
cardiovascular- and non-cardiovascular diseases [22]. In this context,
T1 mapping of the longitudinal relaxation of the myocardium has al-
ready been used to correlate areas of ﬁbrosis to elevated T1 values,
elevated wall thickness, and the extent of LGE [31,32]. T2* mapping, as
another parametric mapping technique, is able to characterize the re-
laxation of the transverse magnetization that is inﬂuenced by macro-
scopic and mesoscopic magnetic ﬁeld inhomogeneities [14,22]. While
macroscopic inhomogeneities are caused by inhomogeneities of the
magnetic ﬁeld, mesoscopic ﬁeld inhomogeneities are inﬂuenced by the
structure of the tissue. As a consequence, T2* value can be reduced due
to structural tissue alterations. From extracardiac tissues it is known,
that the T2* relaxation time in ﬁbrotic intestinal segments of crohn’s
disease as detected by contrast enhancement or in collagen rich tissue
becomes short and these observations have already been veriﬁed by
histologic analyses [18]. From cardiac tissues it is known, that myo-
cardial microstructure can be visualized using T2* imaging at high
magnetic ﬁelds and that reduced T2* values correlated with the area of
myocardial ﬁbrosis or collagen fractional area as determined by his-
tology, even when LGE was inconclusive [33–35]. Despite the inﬂuence
on T2* of extracellular matrix diﬀerences in collagen composition,
another explanation for the reduction of T2* values could be that in
areas of reduced perfusion or ﬁbrosis, oxyhemoglobin and –myoglobin
as local oxygen suppliers are decreased while deoxyhemoglobin and
-myoglobin are increased. In contrast to oxygenated proteins, deox-
ygenated proteins are paramagnetic and therefore reduce local T2*
values. In the present study, patients with HCM, and especially patients
with myocardial ﬁbrosis, exhibited signiﬁcantly reduced T2* values
with a good diagnostic accuracy in logistic regression. As this may
underline the diagnosis of myocardial replacement ﬁbrosis, T2* has the
ability to add diagnostic value in borderline cases or where contrast
agents cannot be applied. In this context, T2* values potentially identify
a sub-group of patients being at higher risk for future cardiac events,
warranting further veriﬁcation of the relation between T2* and ﬁbrosis
in histologic analyses.
In addition to those ﬁndings, the tendency towards decreased T2*
values in the non-ﬁbrosis group may suggest ischemic or structural
alterations in the absence of LGE. Although the current study was
performed under resting conditions, a previous study using blood-
oxygenation level-dependent MR showed a reduced oxygenation in
areas without ﬁbrosis by using stress perfusion [36]. This reduced
oxygenation has been suggested another inﬂuencing factor on T2*
[15,20]. In addition, a higher SD of patients without ﬁbrosis compared
to patients with ﬁbrosis or controls may suggest diﬀerent stages in those
patients.
We could not ﬁnd a correlation between reduction of T2* values and
the amount of replacement ﬁbrosis. Explanations for this could be that
abnormal myocardial perfusion has also been found in areas of normal
wall thickness [8,36]. Further inﬂuencing factors for T2* may also be
the dynamic histopathological states of HCM with a varying degree of
edema, cell death, ﬁber disarray, and myocardial scarring [27].
The following limitations must be acknowledged to our study. Most
of the patients with implantable cardioverter deﬁbrillators had to be
excluded from the study due to safety guidelines. This may have in-
troduced a selection bias by limiting the study group to a lower risk
population.
As the study was conducted retrospectively, we were not able to
quantify perfusion by CMR or verify the relation between T2* and ﬁ-
brosis in histopathologic analyses. However, studies from diﬀerent
tissues have already shown a correlation between T2* values and col-
lagen or LGE [14,16–18]. In addition, microvascular dysfunction in
HCM has already been described in literature and perfusion studies in
CMR have shown good accuracy for the description of microvascular
dysfunction [8,12]. In addition to LGE as widely accepted technique for
the detection of ﬁbrosis, T1 mapping would have been of additional
value to detect interstitial ﬁbrosis [37]. Nevertheless, LGE imaging is
regarded the reference standard to detect myocardial ﬁbrosis and re-
placement ﬁbrosis due to ischemic alterations showed good correlation
to LGE extend during histological analyses underlining feasibility of
LGE to detect ﬁbrosis [25,38,39].
The study was conducted as a single-center study and a multicenter
study could strengthen the above results in the future. In addition, not
all patients were followed over time, therefore hampering the report of
major adverse cardiac events within this study.
5. Conclusions
In conclusion, parametric mapping with CMR identiﬁed a sub-group
of HCM patients with decreased T2* values alongside myocardial re-
placement ﬁbrosis. As myocardial ﬁbrosis has been suggested to inﬂu-
ence the prognosis of patients with HCM, this could be of importance in
certain clinical settings as T2* has the ability to potentially identify a
sub-group of patients being at higher risk for future cardiac events.
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